Dr. Niklas Klümper
Department of Urology and Institute of Experimental Oncology
niklas.kluemper@ukbonn.de View member: Dr. Niklas Klümper
JCO precision oncology
PURPOSE: Lynch syndrome (LS), caused by pathogenic germline variants (PGVs) in DNA mismatch repair (MMR) genes, confers increased risks of colorectal, endometrial, and extracolonic malignancies. Urothelial carcinoma (UC) contributes substantially to LS-associated morbidity and mortality. We assessed its frequency, clinical presentation, genotype-associated risk, and molecular features.
METHODS: We retrospectively analyzed genetically confirmed adult LS carriers in the nationwide German Consortium for Familial Intestinal Cancer registry. UC diagnoses identified by International Classification of Diseases, 10th Revision codes C65-C68 underwent manual clinical and pathologic validation. Available tumors underwent centralized pathologic review, MMR immunohistochemistry, and microsatellite instability (MSI) testing.
RESULTS: Among 3,274 LS carriers, 144 (4.4%) had 224 primary UCs. The median age at first UC was 55 years (range, 22-79 years), and UC was the first malignancy in 50 patients (34.7%). Of 202 tumors with known location, 114 (56.4%) arose in the upper urinary tract. Metachronous and synchronous primary UCs occurred in 23 patients (16.0%) and five patients (3.5%), respectively. -associated PGVs were present in 111 patients (77.1%). In multivariable analysis, carrier status was associated with UC risk (hazard ratio, 4.43 [95% CI, 2.85 to 6.89]), whereas previous colorectal cancer and UC family history were not. Among 109 patients with diagnostic information, 26 (23.9%) presented with urinary tract-related symptoms, 20 (18.3%) were diagnosed incidentally, and 11 (10.1%) were diagnosed during urologic or oncologic surveillance. Of 31 lesions from 18 patients, 29 (93.6%) were mismatch repair-deficient (dMMR) and 30 (96.8%) were MSI-high; all patients had at least one dMMR tumor and at least one MSI-high tumor.
CONCLUSION: UC in LS occurs relatively early, is strongly associated with carrier status, and represents the first malignancy in one third of patients. These findings support prospective evaluation of genotype-adapted surveillance.
PMID: 43024847
Department of Urology and Institute of Experimental Oncology
niklas.kluemper@ukbonn.de View member: Dr. Niklas KlümperMedical Clinic I
jacob.nattermann@ukbonn.de View member: Prof. Dr. med. Jacob Nattermann